Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01120249 · ClinicalTrials.gov registry record · Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,545
- Enrollment target
NCT01120249: Completed Phase 3 study, sponsored by SWOG Cancer Research Network.
NCT01120249 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 1,545 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01120249, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,545 participants
- Enrollment target
Study Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.
Primary Outcome
To compare 5-year recurrence-free survival in renal carcinoma participants randomly assigned to 54 weeks of everolimus versus 54 weeks of placebo after nephrectomy or partial nephrectomy. Recurrence-free survival is defined as From date of registration to date of first documentation of recurrence or death due to any cause. Participants last known to be alive and recurrence-free are censored at date of last contact. Recurrence is defined as positive cytology or biopsy and/or progressively enlargi
Interventions
- OTHER placebo
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,545 participants |
| Start Date | 2011-04-01 |
| Est. Completion | 2025-09-01 |
| Phase | Phase 3 |
What the finished NCT01120249 record still lists
NCT01120249 is an interventional study that assigns participants to a tested intervention. Its 1,545 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01120249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01120249 about?
NCT01120249 is a clinical study titled "S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery". RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.
What is the current status of trial NCT01120249?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,545 participants. The study started on 2011-04-01. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT01120249?
The interventions under investigation include: placebo (OTHER), everolimus (DRUG).
Who is sponsoring clinical trial NCT01120249?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01120249's enrollment target sits among peer trials
1,545 151st of 2000 higher than 1,850 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06729775 · 1,546 participants · NA
Disentangling the Role of Culture, Life Stage, and Information Design to Facilitate Equity in Data Report Back
- NCT03435796 · 1,541 participants · Phase 2
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- NCT02650622 · 1,550 participants
Genetic and Metabolic Disease in Children
- NCT03961945 · 1,550 participants · NA
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI